Home > Research > Browse

Research

Results for Neuroprotective Agents

Publications & Outputs

  1. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease

    McClean, P. L. & Holscher, C., 11/2014, In: Neuropharmacology. 86, p. 241-258 18 p.

    Research output: Contribution to Journal/Magazine › Journal article › peer-review

  2. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease

    Long-Smith, C. M., Manning, S., McClean, P. L., Coakley, M. F., O'Halloran, D. J., Holscher, C. & O'Neill, C., 03/2013, In: NeuroMolecular Medicine. 15, 1, p. 102-114 13 p.

    Research output: Contribution to Journal/Magazine › Journal article › peer-review

  3. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease

    Hölscher, C., 06/2010, In: Recent Patents on CNS Drug Discovery. 5, 2, p. 109-117 9 p.

    Research output: Contribution to Journal/Magazine › Journal article › peer-review

  4. Galantamine inhibits β-amyloid aggregation and cytotoxicity

    Matharu, B., Gibson, G., Parsons, R., Huckerby, T. N., Moore, S. A., Cooper, L. J., Millichamp, R., Allsop, D. & Austen, B., 15/05/2009, In: Journal of the Neurological Sciences. 280, 1-2, p. 49-58 10 p.

    Research output: Contribution to Journal/Magazine › Journal article › peer-review